NOS2 and neoplasm: The results showed that emodin attenuated the inflammatory response in the tumor microenvironment, reduced inflammatory cells CD11b and F4/80 recruitment, and decreased the cytokines tumor necrosis factors alpha (TNFα), interleukin-1 alpha/beta (IL1α/β), IL6, and the pro-inflammatory enzymes cyclooxygenase-2 (COX2) and nitric oxide synthase 2 (NOS2) in the tumor microenvironment.